MediWound Reports Mixed Q4/FY25 Results, Reaffirms 2026-2028 Guidance, Boosts Cash Position
Summary
MediWound reported decreased Q4 and FY2025 revenue but improved full-year net loss, while significantly increasing its cash reserves and reaffirming strong revenue guidance for 2026-2028, alongside pipeline advancements.
Key Events
-
Mixed Q4 and Full Year 2025 Financial Results
Revenue for full year 2025 decreased to $17.0 million from $20.2 million in 2024, and Q4 2025 revenue was $1.9 million, down from $5.8 million in Q4 2024. The full year net loss improved to $23.9 million from $30.2 million in 2024, while Q4 net loss widened to $7.2 million from $3.9 million in Q4 2024.
-
Strong Cash Position and Funding Activities
Cash, cash equivalents, and deposits increased to $53.6 million as of December 31, 2025, up from $43.6 million in 2024. This was bolstered by a $30.0 million registered direct offering and $3.5 million from warrant exercises during 2025.
-
Reaffirmed 2026-2028 Revenue Guidance
The company reaffirmed its revenue guidance, projecting $24-26 million for 2026, $32-35 million for 2027, and $50-55 million for 2028, indicating confidence in future growth despite recent revenue declines.
-
Advancements in Pipeline and Manufacturing
The EscharEx Phase III VALUE trial is progressing as planned, with interim assessment and enrollment completion expected by year-end 2026. The expanded NexoBrid manufacturing facility is now operational, increasing production capacity sixfold, with regulatory approvals anticipated in 2026.
Analysis
MediWound Ltd. reported mixed financial results for Q4 and full year 2025, with a notable decrease in revenue compared to the prior year and quarter, primarily attributed to a U.S. government shutdown and lower product sales. However, the company significantly strengthened its balance sheet, increasing cash, cash equivalents, and deposits to $53.6 million by year-end 2025, partly through a $30.0 million registered direct offering. Crucially, MediWound reaffirmed its revenue guidance for 2026-2028, projecting substantial growth in the coming years, which provides a positive outlook despite the recent revenue challenges. Operational progress on the EscharEx Phase III trial and the expanded NexoBrid manufacturing facility further supports future growth potential. This filing provides the full financial details and detailed guidance that were partially previewed in news reports earlier today.
At the time of this filing, MDWD was trading at $17.20 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $225.9M. The 52-week trading range was $14.14 to $22.51. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.